Acrivon Therapeutics reports FY 2022 net loss $31.2M, cash runway into Q4 2024

Acrivon Therapeutics, Inc.

Net loss for FY 2022 was $31.2M vs $16.2M in 2021; Q4 net loss $8.9M vs $4.3M.
R&D expenses $23.9M in 2022, driven by ACR-368 Phase 2 trial and companion diagnostic agreement.
Cash, cash equivalents and marketable securities $169.6M as of Dec 31, 2022; expected to fund operations at least into Q4 2024.
FDA clearance received for IND of ACR-368 Phase 2 trial in platinum-resistant ovarian, endometrial, and urothelial cancers.
Initial Phase 2 data expected in second half of 2023; WEE1 and PKMYT1 programs advancing toward IND-enabling studies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acrivon Therapeutics, Inc. reported the full year ended December 31, 2022 results: net income $31.2 million.

Period: the full year ended December 31, 2022
Net income: $31.2 million
Result: reported results

Exact text from the filing

Net loss for the quarter and full year ended December 31, 2022 was $8.9 million and $31.2 million, respectively.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acrivon Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: net income $8.9 million.

Period: the fourth quarter ended December 31, 2022
Net income: $8.9 million
Result: reported results

Exact text from the filing

Net loss for the quarter and full year ended December 31, 2022 was $8.9 million and $31.2 million, respectively.

View on SEC.gov

Browse all earnings releases →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-081445

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.